NCT07052097

Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic Rhinitis

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQC2938 Injection Combined With Background Therapy in Patients With Seasonal Allergic Rhinitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 136 (actual)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate TQC2938 injection in all patients receiving background treatment with azelastine fluticasone nasal spray. The efficacy, safety and immunogenicity of the injection in patients with seasonal allergic rhinitis compared with placebo are expected to include 136 patients.

Conditions

• Seasonal Allergic Rhinitis

Interventions

Type	Name	Description
DRUG	TQC2938 injection	TQC2938 injection is a humanized monoclonal antibody that interfering with the signal cascade.
DRUG	TQC2938 Placebo	TQC2938 placebo, 4 weeks as a treatment cycle.

Timeline

• Start date: 2025-07-31
• Primary completion: 2025-09-12
• Completion: 2025-11-28
• First posted: 2025-07-04
• Last updated: 2026-02-10

Locations

30 sites across 1 country: China